www.BioNJ.org
Welcome to BioNJ’s 30th Annual Dinner Meeting and Innovation Celebration honoring the extraordinary medical innovation coming from New Jersey and the Patients who are benefitting from them. Because Patients Can’t Wait®, tonight’s program is dedicated to the Patients, innovators, advocates, policymakers and service providers who are working together to bring new therapies and cures to those around the world in need. The Garden State remains a leading innovation powerhouse – with nearly 50% of all new FDA approvals in 2022 coming from companies with a footprint in New Jersey. And, tonight we are proud to present those New Jersey companies with a BioNJ Innovator Award. Similarly, we are pleased to present the Heart of BioNJ Award to Maria Kafalas, Founder of The Calliope Joy Foundation, who will share her family’s incredible journey with us this evening. We are delighted to once again have the dear Dr. Sol J. Barer with us to present the 15th Annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership to Dr. David Perlin, Chief Scientific Officer and Executive Vice President for the Hackensack Meridian Center for Discovery and Innovation. Well recognized for his innovative and entrepreneurial leadership in biomedical sciences, Dr. Perlin is an accomplished researcher and visionary in the development of novel therapies to detect, combat and prevent deadly infections. Please enjoy tonight’s festivities as we mark another year of success for the New Jersey ecosystem and the 30th year of BioNJ. As always at BioNJ, we have many people to thank for their generosity, dedication and contributions to making this meeting possible. We are indebted to our dedicated Board of Trustees, our creative Annual Dinner Meeting Committee chaired by Dr. Andrew Latham of Merck & Co. and Marisol Mendez Peron of Genmab, our generous Sponsors, New Jersey’s vibrant life sciences ecosystem and our talented BioNJ Team. Thank you one and all for being here. Because Patients Can’t Wait®, Will H. Lewis, JD, MBA Debbie Hart Board Chair President & CEO BioNJ BioNJ Chair & CEO Insmed Because Patients Can’t Wait® Because Patients Can’t Wait ® 1
CHAIR Will Lewis, JD, MBA Chair & CEO Insmed PRESIDENT & CEO Debbie Hart, MS, APR BioNJ IMMEDIATE PAST CHAIR Christopher J. Schaber, Ph.D. Chair, President & CEO Soligenix TREASURER Jeffrey A. Nau, Ph.D., MMS President & CEO Viatris SECRETARY Michele Korfin, R.Ph., MBA Chief Operating Officer & Chief Commercial Officer Gamida Cell BOARD MEMBERS Sol J. Barer, Ph.D. Former Chair & CEO Celgene Corporation Chair of the Board Teva Pharmaceutical Industries Carrie Brown Head, U.S. Communications Sanofi Amadou Diarra, Ph.D. Senior Vice President, Global Policy, Advocacy & Government Affairs Bristol Myers Squibb Jayne C. Gershkowitz Chief Patient Advocate Amicus Therapeutics Emer Leahy, Ph.D., MBA President & CEO PsychoGenics Susan L. Levinson, Ph.D. CEO BioAegis Therapeutics John Maki CEO Bayesian Biotech Anthony S. Marucci, MBA Founder, President, CEO & Director Celldex Therapeutics Scott Megaffin President & CEO Adiso Therapeutics Christopher Mortko, Ph.D., MBA Associate Vice President & Head, HQ Search & Evaluation Merck Business Development & Licensing Andrew L. Pecora, M.D., FACP, CPE Chair & CEO, Outcomes Matter Innovations, LLC Stuart W. Peltz, Ph.D. CEO PTC Therapeutics Spiro Rombotis, MPH, MBA President & CEO Cyclacel Pharmaceuticals Bob Smith Senior Vice President, Global Gene Therapy Business & Early Commercial Development, Rare Disease Business Unit, Pfizer Biopharmaceuticals Group Pfizer Marco Taglietti, M.D. President & CEO SCYNEXIS BOARD ADVISORS ACADEMIC ADVISOR Reynold A. Panettieri, Jr., M.D. Professor of Medicine, Robert Wood Johnson Medical School; Vice Chancellor, Clinical & Translational Science & Director, Rutgers Institute for Translational Medicine & Science Emeritus Professor of Medicine, University of Pennsylvania & Rutgers, The State University of New Jersey ACCOUNTING ADVISOR Brian Wilcomes Principal Strategy & Analytics Deloitte & Touche INVESTOR ADVISOR George Heinrich, M.D. Vice Chair & CEO New Jersey Health Foundation & Foundation Venture Capital Group, LLC (FVCG) LEGAL ADVISOR Emilio Ragosa Managing Partner DLA Piper STATE GOVERNMENT OFFICIAL ADVISOR Kathleen Coviello Chief Economic Transformation Officer New Jersey Economic Development Authority (NJEDA) ADDITIONAL ADVISORS Teresa Leste Principal, Life Sciences Strategy & Analytics Deloitte Gregory Oakes, MBA President & CEO Landos Biopharma James Sapirstein, R.Ph., MBA President, Chair & CEO First Wave BioPharma 2022 BioNJ Board of Trustees 2
Andrew H. Latham, Ph.D. – Co-Chair Merck & Co. Marisol Mendez Peron – Co-Chair Genmab Hayley Alexander BeiGene USA James Bruno, MBA Chemical & Pharmaceutical Solutions John Cahill Jones Lang LaSalle Marshall Calman, MBA, PCC LeaderStrong Richard Clements WhizAI Bill DeStefano Marsh Mandy Fahey Insmed Nikki Frazier Centri Business Consulting, LLC Jayne Gershkowitz Amicus Therapeutics Darek Hahn Cereberus Sentinel Ethan Hasbrouck Bristol Myers Squibb Tracy Henrikson, MBA Eli Lilly & Company Paul Howard, P.h.D Amicus Therapeutics Jack Levitt, MBA, EMTM LeaderStrong Wyman Morgan Infinity Resources, LLC Christopher Schaber, Ph.D. Soligenix Judith Sheft, MBA, MSc New Jersey Commission on Science, Innovation & Technology Ebony Staton Weidman Janssen Alain Van Loo Assetive Joel Wagner, CPA EY Jordan Warshafsky, MBA Ashton Tweed, LTD Brian Wilcomes, CPA Deloitte & Touche Debbie Hart President & CEO [email protected] Randi Bromberg Sr. Vice President Communications & Marketing [email protected] Maria Carapucci Meeting Coordinator [email protected] Donna Gibbons Sr. Vice President, Operations [email protected] Cheri Hennessy Vice President, Member Engagement & Strategic Partnerships [email protected] Pavita Howe, MBA Vice President, Innovation & Entrepreneurship [email protected] Ian McLaughlin, Ph.D. Vice President, Government Affairs [email protected] Denise Machado Executive Director, Member Operations [email protected] Debbie Mennito Executive Director, Conferences, Committee & Workforce [email protected] Dawn Piccioni Director, Marketing & Design [email protected] Cheri Potts Office Manager [email protected] Dana Sacco Sr. Executive Assistant to the CEO [email protected] Peggy Schell Talent Services & Public Policy Assistant [email protected] Ann Wieczkowski Executive Director, Accounting Operations [email protected] BioNJ TEAM 2023 Annual Dinner Meeting Committee Members 3
30TH ANNIVERSARY SPONSOR Hackensack Meridian Health DREAM MAKER SPONSORS Biotechnology Innovation Organization ♦ Bristol Myers Squibb Genmab ♦ Insmed ♦ New Jersey Health Foundation ♦ Pfizer PTC Therapeutics ♦ Thermo Fisher Scientific TABLE SPONSORS Amicus Therapeutics ♦ Conner Strong & Buckelew Deloitte ♦ Eisai ♦ Eli Lilly ♦ EY ♦ Faegre Drinker Gilead Sciences ♦ Mercer/Marsh ♦ Matinas BioPharma McKinsey & Company ♦ Melinta Therapeutics ♦ Morgan Stanley ♦ Novartis Princeton University ♦ Regional Cancer Care Associates ♦ RSM US Rutgers Office for Research ♦ Sampled ♦ Teva Pharmaceuticals USI Insurance ♦ Venable ♦ Viatris Thank You to Our Sponsors 4
COCKTAIL SPONSORS DLA Piper ♦ Kyowa Kirin ♦ Lachman Consultants ♦ Merck & Co. PHC Corporation of North America ♦ Sanofi DESSERT SPONSORS Ascendia Pharma ♦ Barnes & Thornburg ♦ BieGene Centri Business Consulting ♦ Janssen Pharmaceuticals New Jersey Manufacturing Extension Program (NJMEP) Nikon ♦ Phathom Pharmaceuticals ♦ PHL Life Sciences PsychoGenics ♦ SciSafe MEDIA SPONSORS NJBIZ ♦ New Jersey Business Magazine VIDEO SPONSOR Pulse Productions Tweet about BioNJ’s Annual Dinner Meeting and Innovation Celebration! #PatientsCantWait 5
THE BOARD OF TRUSTEES OF BioNJ WELCOMES YOU TO THE 2023 ANNUAL DINNER MEETING, NETWORKING EVENT AND INNOVATION CELEBRATION February 2, 2023 Hilton East Brunswick 4:45 p.m. – 5:45 p.m. Networking Reception 6:00 p.m. – 8:30 p.m. Dinner Program, Networking and Innovator Awards 8:30 p.m. – 9:30 p.m. Dessert and Networking Reception OPENING CEREMONIES WELCOME Debbie Hart President & CEO, BioNJ 6
LEADERSHIP TRANSITION Will Lewis, JD, MBA Chair & CEO, Insmed Amadou Diarra, Ph.D. Senior Vice President, Global Policy, Advocacy & Government Affairs Bristol Myers Squibb INNOVATOR AWARDS DINNER AND NETWORKING THE DR. SOL J. BARER AWARD FOR VISION, INNOVATION AND LEADERSHIP Presented by Sol J. Barer, Ph.D. Former Chair & CEO, Celgene Corporation and Chair of the Board, Teva Pharmaceutical Industries to David S. Perlin, Ph.D. Chief Scientific Officer & Executive Vice President Hackensack Meridian Center for Discovery and Innovation HEART OF BioNJ AWARD Presented to Maria Kefalas Founder, The Calliope Joy Foundation DESSERT AND NETWORKING RECEPTION Saluting Innovators and the Patients Who Inspire Them 7
• Boehringer Ingelheim for Spevigo® • Bristol Myers Squibb for Camzyos™, Opdualag™ & Sotyktu™ • Eli Lilly and Company for Mounjaro® • Ferring Pharmaceuticals for Adstiladrin® & Rebyota™ • Gilead Sciences for Sunlenca® • Glenmark Pharmaceuticals for Ryaltris® • GSK for Priorix • Guerbet for Elucirem™ • Idorsia for Quviviq™ • Janssen Pharmaceutical Companies of Johnson & Johnson for Carvykti™ & Tecvayli™ • Mallinckrodt Pharmaceuticals for Terlivaz® • Novartis for Pluvicto™ • Pfizer for Cibinqo™ • Phathom Pharmaceuticals for Voquezna™ • Provention Bio for Tzield™ • Sanofi for Enjaymo™ & Xenpozyme™ • Sun Pharmaceutical for Sezaby™ • Taiho Oncology for Lytgobi® • TG Therapeutics for Briumvi™ Innovator Awards Honoring 2022 FDA Approvals 8
Maria Kefalas is the founder of The Calliope Joy Foundation/Cure MLD and the author of numerous books and articles, including her 2021 memoir titled Harnessing Grief. Maria became an advocate for gene therapy after the diagnosis of her late daughter Calliope (Cal) at age 2 with a neurodegenerative disorder called metachromatic leukodystrophy (MLD). Maria Kefalas Founder, The Calliope Joy Foundation 2023 Heart of BioNJ Award Honoree 9 Since 2013, Maria has spoken to the FDA and NIH about the promise of genomic medicine. In 2018, she received the Rare Impact Award from the National Organization of Rare Disorders (NORD). Her work as an advocate has been featured by the Chan Zuckerberg Initiative, NPR, The Philadelphia Inquirer, The Huffington Post, CBS Sunday Morning with Jane Pauley, STAT and Slate.
Sol J. Barer, Ph.D. Former Chair & CEO Celgene Corporation Chair of the Board Teva Pharmaceutical Industries Dr. Barer spent most of his professional career with the Celgene Corporation. He was Chair from January 2011 until June 2011, Executive Chair from June 2010 until January 2011 and Chair and Chief Executive Officer from May 2006 until June 2010. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr. Barer was the Founder of the biotechnology group at the Celanese Research Company which was subsequently spun out to form Celgene. Dr. Barer currently serves as Chair of the Board of the public companies Teva Pharmaceutical Industries and Neximmune and the private company Centrexion, is a Director of 3D Biotherapeutics and Zephyr.ai, and is Lead Director of the public company ContraFect. He is the Founding Chair of the HMH Center for Discovery and Innovation. Dr. Barer is a Founder of MIG, an organization dedicated to helping Israeli biotech entrepreneurs and is a Venture Advisor to the Israel Biotechnology Fund as well as an advisor to biopharma companies. In 2011, Dr. Barer was Chair of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee which resulted in sweeping changes in the structure of New Jersey’s medical schools and public research universities. He previously served as a Commissioner of the NJ Commission on Science and Technology. He was a member of the Board of Trustees of Rutgers University (until 2013). He also served two terms as Chair of the Board of Trustees of BioNJ. Dr. Barer was named to the “Worldview 100” (Scientific American’s 100 most influential figures in today’s world of biotechnology) in 2015, named one of “25 Leadership Legends of NJ” (NJBIZ) in 2012, “The 50 Most Powerful People in NJ Health Care,” in 2012, inducted into the NJBIZ Hall of Fame in 2011 and was named as one of NJ’s top 10 scientists by New Jersey Business Magazine in 2008. Dr. Barer has received numerous professional awards. The Dr. Sol J. Barer Award for Vision, Innovation and Leadership 10
Dr. David S. Perlin is a highly accomplished biomedical researcher and chief executive who is well recognized for his innovative and entrepreneurial leadership in the biomedical sciences. He is the inaugural Chief Scientific Officer and Executive Vice President for the Hackensack Meridian Center for Discovery and Innovation (CDI), which seeks to rapidly translate innovations in science to improve outcomes for Patients with cancer, infectious diseases, and other acute and chronic disorders. In under four years, he has built an organization with 26 lab heads, 170 scientists and support staff with an annual operating budget of $52 million funded by 90 grants and contracts including 58 NIH grants. Dr. Perlin has been engaged for >30 years in developing molecular insights and technologies to detect, combat and prevent deadly infections. He is an expert in drug discovery and drug resistance mechanisms, and he has helped develop novel therapeutics and diagnostics against high-threat bacteria, viruses, including some with FDA designation. Previously, he was Executive Director of the Rutgers New Jersey Medical School’s Public Health Research Institute (PHRI). He was also Director of the Rutgers Regional Biocontainment Laboratory (RBL), one of thirteen NIH-designated national centers for pathogen research, and a Professor of Microbiology, Biochemistry and Molecular Genetics. As Executive Director, PHRI attracted >$200 million in research funds and produced more than $100 million in licensing income. Currently, he leads a $33 million NIH-designated national Center of Excellence in Translational Research to discover novel anti-infectives against drug resistant bacterial infections. He also co-leads with Rockefeller University Nobel Laureate Dr. Charles Rice the Metropolitan Antiviral Drug Accelerator, one of nine national centers funded for $108 million under the NIH AViDD program to develop novel small molecule antiviral drugs against SARS-CoV-2 and other pandemic viruses. During COVID-19, his group established one of the first FDA EUA-approved COVID-19 molecular tests for a healthcare system. They jointly developed a highly successful high-titer convalescent plasma therapy program for hospitalized COVID-19 Patients; they engaged in drug discovery against SARS-CoV-2 with pharma and biotech partners, and they developed high-throughput technology for the assessment of virus variants of concern. David S. Perlin, Ph.D. Chief Scientific Officer & Executive Vice President Hackensack Meridian Center for Discovery and Innovation The 2023 Dr. Sol J. Barer Award for Vision, Innovation and Leadership Recipient 11
Thank You to Our Upper Tier Members MARKET MAKER PREFERRED EXECUTIVE 12
Innovation & Associate A.J. O’Connor Associates AbbVie Inc. Acadia Pharmaceuticals Adare Pharma Solutions ADC Therapeutics Adiso Therapeutics, Inc. ADMA Biologics, Inc. Admera Health Advanced Accelerator Applications Advaxis, Inc. Agile Therapeutics, Inc. Airgas East Amarin Pharma, Inc. AMGEN Amici Clinical Research LLC Amicus Therapeutics, Inc. Antios Therapeutics Apprentice.io Ascelia Pharma Ascendia Pharmaceuticals, LLC Ashton Tweed, LTD Aspirant Assetive Avotres Inc. Ayma Therapeutics, Inc. AyurvedicDoc LLC BalinBac Therapeutics, Inc. Barer & Son Capital, LLC Barnes & Thornburg Bayesian Biotech BDO USA, LLP BeiGene Bezwada Biomedical, LLC BioAdvance BioAegis Therapeutics Inc. BioCentriq BioEnsemble LLC Biogen BioMarin Pharmaceutical Inc. BIOTRIAL, Inc. Birch Benefits, LLC Boehringer Ingelheim Animal Health USA Inc. Bristol Myers Squibb Company Buchanan Ingersoll & Rooney PC CAI - Commissioning Agents, Inc. CBIZ Insurance Services, Inc. CBRE Cellares Corporation Celldex Therapeutics, Inc. Celsion Corporation Celularity Inc. Centri Business Consulting CFGI CGI Chartwell Partners Chemical and Pharmaceutical Solutions Chromocell Corporation Chugai Pharma USA, Inc. Clinical Genomics CMIC CMO USA CohnReznick LLP Comprehensive Consulting & Management, LLC Conner Strong & Buckelew ConSynance Therapeutics Control Associates, Inc. Controlled Contamination Services Cornerstone Pharmaceuticals, Inc. Cornerstone Search Group, LLC CRB Cresa Global Inc. Crowley Law LLC Crystal Pharmatech, Inc. CSS Building Services, Inc. Cushman & Wakefield of NJ, LLC Cyclacel Pharmaceuticals, Inc. Deloitte Delphine Diagnostics Inc. Delta Dental of New Jersey Delve Therapeutics DLA Piper LLP Duke Energy Sustainable Solutions DZS Clinical Services, Inc. Edenbridge Pharmaceuticals, LLC EisnerAmper Eli Lilly and Company Emericlin EmphyCorp Inc. Enalare Therapeutics Inc. Erica Ferry & Associates LLC eSTARHelper LLC Evotec, Inc. Evrys Bio, LLC EY US LLP Faegre Drinker Biddle & Reath Ferring Pharmaceuticals, Inc. First Republic Bank First Wave BioPharma, Inc. Fisher Scientific Company LLC Fosun Pharma USA Inc. Gamida Cell Geistlich Pharma North America, Inc. Genentech GENEWIZ, LLC Genmab Gennao Bio Genomic Prediction Inc. Gilead Sciences Inc. Greenwich Biosciences GSG Scientific, LLC GSK Hart & Chin Associates, LLC Helsinn Therapeutics, Inc. Hepion Pharmaceutics Inc. Herspiegel Consulting LLC Hetero USA Hillstream BioPharma Inc. HLW Architecture, LLC Hongyi Therapeutics Horizon Therapeutics HotSpot Therapeutics Hovione LLC Hurley Consulting Associates, Ltd. IBM ImprimisRx LLC Incedo, Inc. Insmed Incorporated Integrated Project Management Company, Inc. Interius BioTherapeutics, Inc. Intrommune Therapeutics IVERIC bio Because Patients Can’t Wait ® BioNJ Members as of 2/1/2023 13
BioNJ Members as of 2/1/2023 Because Patients Can’t Wait ® J-STAR Research, Inc. Jackson Lewis P.C. Javan Engineering & Construction Jesra Advisors, LLC Johnson & Johnson (Janssen) Jones Lang LaSalle JPMorgan Chase Bank NA Jubilant Therapeutics Inc. Kanvas Biosciences, Inc. KatalX Katten Muchin Rosenman LLP Kenox Pharmaceuticals, Inc. Korn Ferry International Kyowa Kirin, Inc. Lachman Consultant Services, Inc. Lactiga, Inc. Landos Biopharma LeaderStrong Legend Biotech USA, Inc. LifeSci Partners Lisata Therapeutics, Inc. Lowenstein Sandler LLP Magic Hat Consulting Mancino Burfield Edgerton Marcum LLP Marsh Inc. Matinas BioPharma Holdings, Inc. MBrace Therapeutics, Inc. McCarter & English LLP McKinsey & Company Medifvu, LLC Medix Melinta Therapeutics Mercer Health & Benefits LLC Merck & Co., Inc. MetasTx, LLC MG Miller Intellectual Property Law LLC Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, PC Mitsubishi Tanabe Pharma America, Inc. MMR Consulting Inc. Mnemo Therapeutics, Inc. Modal Technology Corporation Modern Meadow Inc. Morgan Lewis Morgan Stanley NAKI Therapeutics NDA Group Nevakar, Inc. Nexomics Biosciences, Inc. NJ Bio, Inc. New Jersey Health Foundation NovaRock Biotherapeutics, Ltd. Novartis Pharmaceuticals Corporation Novo Nordisk Nucleus Network Oncosec Medical Incorporated OncoSTING Optinose Organon OrthogenRx, Inc. OsseoPrint 3D Otsuka America Pharmaceutical, Inc. Outlook Therapeutics, Inc. Ovid Therapeutics Palatin Technologies, Inc. Panavance Therapeutics Inc. Passage Bio PendoTECH Peroff Saunders P.C. Pfizer Inc. PhageNova Bio, Inc. Pharmacosmos Therapeutics Pharmatech Solutions LLC Phathom Pharmaceuticals Phio Pharmaceuticals Corp. PHP Environmental Consulting, Inc. PMV Pharmaceuticals, Inc. PNC Bank Porzio, Bromberg and Newman P.C. PR Newswire PricewaterhouseCoopers, LLP Princeton Property Partners, LLC Promed Bioscience Ltd. Prosper Digital Therapeutics, Inc. PsychoGenics Inc. PTC Therapeutics, Inc. Radford/Aon Recordati Rare Diseases Regeneron Pharmaceuticals reVision Therapeutics, Inc. RSM US LLP Sampled Sanguine Biosciences Sannova Analytical Sanofi Sarcoidosis Diagnostic Testing LLC Sauvie Inc. Science Branding Communications SciMar ONE, Inc. SciSafe, Inc. Scynexis, Inc. Sellas Life Sciences Group SHINKEI Therapeutics Signum Biosciences, Inc. Silence Therapeutics Silicon Valley Bank Simphotek Inc. Soligenix, Inc. Somnia Therapeutics, LLC Sonder Research X Sonnet BioTherapeutics, Inc. Starton Therapeutics Stone Creek Construction Group LLC Strategies for Success Int’l Streetworks Development/ Hudson Labs Tactical Therapeutics, Inc. Taiho Oncology, Inc. Talking Medicines Limited TAXIS Pharmaceuticals, Inc. Tech Council Ventures Teclison USA Limited TEVA Pharmaceuticals Tevogen Bio Inc. The Cove JC TrialSpark Ubuntu Research Inc. Urigen Pharmaceuticals, Inc. USI Insurance Services VelocIT Vertex Pharmaceuticals Verve Group Consulting Viatris Vifor Pharma Vitalief Inc. 14
BioNJ Members as of 2/1/2023 Because Patients Can’t Wait ® Vyome Therapeutics Inc. WhizAI WithumSmith+Brown, PC Worldwide IP Solutions LLC WuXi Biologics Y-mAbs Therapeutics, Inc. Institution Center for Healthcare Innovation, Stevens Institute of Technology Choose New Jersey Coriell Institute for Medical Research ExportJERSEY Hackensack University Medical Center Institute for Life Science Entrepreneurship Kean University Mid-Atlantic - Eurasia Business Council New Jersey Business & Industry Association New Jersey Economic Development Authority (NJEDA) New Jersey Institute of Technology (NJIT) New Jersey State Chamber of Commerce Office of Business Engagement, Middlesex County PA Biotechnology Center Princeton Innovation Center BioLabs Princeton Mercer Regional Chamber Princeton University Rowan University Rutgers, The State University of New Jersey Seton Hall Law School Somerset County Business Partnership Somerset County Office of Planning, Policy and Economic Development Students 2 Science, Inc. TechUnited:NJ The College of New Jersey (TCNJ) We Work For Health Patient Advocacy Adult Polyglucosan Body Disease Research Foundation AliveAndKickn American Behcet’s Disease Association American Cancer Society American Diabetes Association Armor Up for Life Brooke Healey Foundation CancerCare CheckRare Children’s Cardiomyopathy Foundation CJD Foundation Community Liver Alliance Congenital Hyperinsulinism International Crohn’s & Colitis Foundation, NJ Chapter Crossroads4Hope Curemonos Danon Disease Foundation, Inc. EveryLife Foundation for Rare Diseases EverythingALS Familial Dysautonomia Foundation Global Genes Global Lyme Alliance HEADstrong Foundation Hepatitis B Foundation Hope Loves Company Hypertrophic Cardiomyopathy Association IGA Nephropathy Foundation of America Immune Deficiency Foundation International Cancer Advocacy Network (ICAN) Kaleidoscope of Hope Ovarian Cancer Foundation Lung Cancer Circle of Hope Lupus and Allied Diseases Association MSA NJ Multiple Sclerosis Association of America My Life Is Worth It NAMI New Jersey National Infusion Center Association National Kidney Foundation National Multiple Sclerosis Society, NJ Metro Chapter National Organization for Rare Disorders (NORD) Neurofibromatosis, Inc. Northeast New Jersey Association of Mental Health and Addiction Agencies, Inc. (NJAMHAA) New Jersey Center for Tourette Syndrome and Associated Disorders Inc. Patient Access Network (PAN) Foundation Professional Patient Advocates in Life Sciences Project 8p Sepsis Alliance Susan G. Komen North Jersey The Family Resource Network The Leukemia & Lymphoma Society Thea’s Star of Hope U.S. Pain Foundation Advisory Biotechnology Innovation Organization Princeton Public Affairs Group International Hikal LTD Flanders Investment & Trade 15
BioNJ Salutes Our Sponsors 16
CONGRATULATIONS TO ALL AWARD WINNERS IN ALL CATEGORIES The Dr. Sol J. Barer Award, the Innovator Awards and the Annual Heart of BioNJ Awards LOOKING FORWARD. GIVING BACK. INSURANCE RISK MANAGEMENT EMPLOYEE BENEFITS CONNERSTRONG.COM George E. Norcross III, Executive Chairman Joseph Buckelew, Chairman Michael Tiagwad, President and Chief Executive Officer Daniel S Brettler, Senior Partner, National Life Science Practice Leader
The biotechnology industry is saving lives in New Jersey, and beyond. BIO’s member companies develop breakthroughs every day. Biotechnology innovators are bringing COVID-19 vaccines to patients around the globe, creating sustainable fuels, and developing agricultural innovations to increase yields and feed more people. BIO. Where breakthroughs begin.
In the future, health care as we know it will no longer exist. The industry will be defined by radically interoperable data, open yet secure platforms, and consumer-driven care. What role will you play? Now is the time to engineer your advantage. www.deloitte.com/future Realizing the Future of Health™
When the human body is the biggest data platform, who will capture value? In this Transformative Age, technology is helping reimagine industries in limitless ways. ey.com/lifesciences #BetterQuestions ©2023 Ernst & Young LLP. All Rights Reserved. 2202-3977174 | ED None. © 2023 Faegre Drinker Biddle & Reath LLP. All Rights Reserved. 553086 faegredrinker.com Collaborators Who Care Whether you’re overcoming regulatory and compliance hurdles, pursuing strategic transactions, advancing public policy initiatives or navigating complex litigation and enforcement matters, our multidisciplinary health and life sciences team is dedicated to your success.
WHAT WE LIVE FOR, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc. © 2020 Gilead Sciences, Inc. All rights reserved. UNBC7887 12/20 GILEAD IS A PROUD SPONSOR OF BioNJ GileadHIV.com @gileadhivus @GileadHIVUS We are an international biotech company committed to improving the lives of antibody medicines. genmab.com Working to transform the future of cancer treatment
insmed.com Infi nite potential. One patient at a time. © 2023 Insmed Incorporation. All Rights Reserved. Insmed and the Insmed logo are trademarks of Insmed.
www.LachmanConsultants.com www.KyowaKirin.com
McKinsey & Company is proud to support BioNJ’s 2023 Annual Dinner Meeting & Innovation Celebration. We warmly congratulate tonight’s honorees! www.MatinasBiopharma.com
©2023 Melinta Therapeutics LLC. All rights reserved. Get inspired at Melinta.com We Are Melinta. We are visionaries striving to provide innovative therapies for acute and life-threatening illnesses. We go where patients are, to ensure that all people who need our therapies receive them. We are passionate about our unparalleled commitment to our mission, our patients and one another. We are Melinta. Evolving, growing, leading, serving. #BeLegendary Marsh and Mercer are proud supporters of BioNJ. Congratulations to all the 2023 award recipients. Our purpose is Possibility. We seek better ways to manage risk and human capital and define more effective paths to the right outcome. Marsh – Risk & Insurance Services Consulting: Insurance Broking & Risk Management Mercer – Health, Wealth & Career Consulting
We invent because the world still needs cures for cancer, Alzheimer’s disease, HIV, and so many other causes of widespread suffering. Building strong partnerships is critical to solving these challenging diseases – so we can help people go on, unburdened, to experience, create, and live their best lives. Together we can invent more. merck.com/licensing Merck Business Development and Licensing Merck & Co., Inc., Kenilworth, New Jersey, USA is known as MSD outside of the United States and Canada. Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. 02-23 Invent with us
Congratulations on the 30th Anniversary of BioNJ New Jersey Health Foundation and its affiliate Foundation Venture Capital Group join BioNJ to honor the vision, innovation, and leadership of David S. Perlin, Ph.D. Dean Janeway Chair George F. Heinrich, M.D. Vice Chair & CEO James M. Golubieski President
PROUD MEDIA SPONSOR: BIONJ 2023 ANNUAL DINNER MEETING Would like to CONGRATULATE DR. DAVID PERLIN on being awarded the Dr. Sol J. Barer Award, as well as the winners of The Innovator Awards. JUNE 2023: 32ND ANNUAL INNOVATIVE STATE EDITION READ THE DIGITAL ISSUE NOW NJBMAGAZINE.COM
pHcbi Congratulations BioNJ, for 30 years of driving innovation.
Nomination deadlines and event dates are subject to change, visit njbiz.com/events for details. NJBIZ EVENT NOMINATIONS NOW OPEN NOMINATE NOW AT NJBIZ.COM/EVENTS Questions? Contact [email protected]. For sponsorship opportunities, contact Ken Kiczales at [email protected]. NOMINATION DEADLINE: SEPTEMBER 24 NOMINATION DEADLINE: AUGUST 6 NOMINATION DEADLINE: APRIL 14 2023 NOMINATION DEADLINE: JUNE 4 A program of 2022 NOMINATION DEADLINE: APRIL 9 NOMINATION DEADLINE: JULY 2 NOMINATION DEADLINE: SEPTEMBER 10 A program of NOMINATION DEADLINE: MARCH 5 NOMINATION DEADLINE: FEBRUARY 14 A program of
TRANSLATING SCIENCE Transforming Lives Extending life’s moments for people living with rare diseases For PTC Therapeutics, our 25-year history has been filled with bold transformative science delivering on our commitment to bringing more moments to patients and their families living with rare diseases. See how we are pushing the boundaries of innovation at www.ptcbio.com.
excellence is earned Rutgers is uncovering ways to prevent and treat this disease that afflicts millions. CLOSING THE GAP ON A CURE FOR ALZHEIMER’S excellence is earned Visit rsmus.com/aboutus for more information regarding RSM US LLP and RSM International. Thinking about your business is a big part of ours. PUT OUR LIFE SCIENCES INSIGHTS TO WORK FOR YOU. To make confident decisions about the future, middle market leaders need a different kind of advisor. One who starts by understanding where you want to go and then brings the ideas and insights of an experienced global team to help get you there. Experience the power of being understood. Experience RSM. rsmus.com/lifesciences
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. We are dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. www.sanofi.com www.sanofi.us We never settle Pierre-Marie Robin, Sales, France
www.USI.com
CA | DC | DE | FL | IL | MD | NY | VA 23-013 Venable Proudly Supports The 30th Annual Dinner Meeting and Innovation Celebration We are pleased to join BioNJ in celebrating New Jersey’s vibrant life sciences community. Dominick A. Conde, Esq. | 1290 Avenue of the Americas, 20th Floor, New York, NY Attorney advertising. www.Viatris.com
Hackensack Meridian Health is proud to support BioNJ on the occasion of its 2023 ANNUAL DINNER MEETING & INNOVATION CELEBRATION. Congratulations to DR. DAVID PERLIN, Chief Scientific Officer and Executive Vice President for the Hackensack Meridian Center for Discovery and Innovation, on receiving the Dr. Sol J. Barer Award for Vision, Innovation and Leadership. Best wishes for a successful event. HackensackMeridianHealth.org
CHAIR Amadou Diarra, Ph.D. Senior Vice President, Global Policy, Advocacy & Government Affairs Bristol Myers Squibb VICE CHAIR Emer Leahy, Ph.D., MBA President & CEO PsychoGenics IMMEDIATE PAST CHAIR Will Lewis, JD, MBA Chair & CEO Insmed PRESIDENT & CEO Debbie Hart, MS, APR BioNJ TREASURER Jayne C. Gershkowitz Chief Patient Advocate Amicus Therapeutics SECRETARY Christopher Mortko, Ph.D., MBA Associate Vice President & Head, HQ Search & Evaluation Merck Business Development & Licensing BOARD MEMBERS Sol J. Barer, Ph.D. Former Chair & CEO Celgene Corporation Chair of the Board Teva Pharmaceutical Industries Maya Bermingham, JD Senior Vice President, Public Policy & Government Affairs Regeneron Carrie Brown Head, U.S. Communications Sanofi Samuele Butera, MPP President Janssen Pulmonary Hypertension and Retina Christopher Cozic Executive Vice President & Chief People Officer Genmab Michele Korfin, R.Ph., MBA Chief Operating Officer & Chief Commercial Officer Gamida Cell Susan L. Levinson, Ph.D. CEO BioAegis Therapeutics John Maki CEO Bayesian Biotech Leverne Marsh Chief Product Officer Novartis Pharmaceuticals US BIO Anthony S. Marucci, MBA Founder, President, CEO & Director Celldex Therapeutics Scott Megaffin President & CEO Adiso Therapeutics Christine Miller, MBA President & CEO Melinta Therapeutics Jeffery A. Nau, Ph.D., MMS President & CEO Viatris Gregory Oakes, MBA President & CEO Landos Biopharma Andrew L. Pecora, M.D., FACP, CPE Chair & CEO, Outcomes Matter Innovations, LLC Stuart W. Peltz, Ph.D. CEO PTC Therapeutics Spiro Rombotis, MPH, MBA President & CEO Cyclacel Pharmaceuticals Christopher J. Schaber, Ph.D. Chair, President & CEO Soligenix Michael Schoen Chief of Staff BeiGene Bob Smith Senior Vice President, Global Gene Therapy Business and Early Commercial Development, Rare Disease Business Unit, Pfizer Biopharmaceuticals Group Pfizer BOARD ADVISORS ACADEMIC ADVISOR Reynold A. Panettieri, Jr., M.D. Professor of Medicine, Robert Wood Johnson Medical School; Vice Chancellor, Clinical & Translational Science & Director, Rutgers Institute for Translational Medicine & Science Emeritus Professor of Medicine, University of Pennsylvania & Rutgers, The State University of New Jersey ACCOUNTING ADVISOR Brian Wilcomes Principal Strategy & Analytics Deloitte & Touche INVESTOR ADVISOR George Heinrich, M.D. Vice Chair & CEO New Jersey Health Foundation, Inc., & Foundation Venture Capital Group, LLC (FVCG) LEGAL ADVISOR Emilio Ragosa Partner & Managing Partner DLA Piper STATE GOVERNMENT OFFICIAL ADVISOR Kathleen Coviello Chief Economic Transformation Officer New Jersey Economic Development Authority (NJEDA) TECHNOLOGY ADVISOR Kelly Watson Vice President & Senior Partner IBM Consulting ADDITIONAL ADVISORS Teresa Leste Principal, Life Sciences Strategy & Analytics Deloitte James Sapirstein, R.Ph., MBA President, Chair & CEO First Wave BioPharma 2023 BioNJ Board of Trustees 41
Awards 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 46 47 48 49 50 51 52 53 54 55 STAGE 24 25 26 27 28 29 30 31 32 33 34 56 35 36 37 38 39 40 41 42 43 44 45 57 42
RESERVED TABLES Amicus Therapeutics...................... 26 BioNJ Board of Directors................. 6 BioNJ Board of Directors................. 7 BioNJ Board of Directors............... 17 BioNJ Board of Directors............... 18 BIO ................................................. 14 Bristol Myers Squibb...................... 15 Conner Strong & Buckelew............ 32 Deloitte .......................................... 34 Eisai Inc .......................................... 42 Eli Lilly ............................................ 39 EY ................................................... 37 Faegre Drinker............................... 22 Genmab.......................................... 20 Gilead Sciences .............................. 28 Hackensack Meridian Health ........... 4 Hackensack Meridian Health .......... 5 Innovator / Heart of BioNJ Honorees .. 8 Innovator Honorees ........................ 9 Insmed.............................................. 3 Matinas........................................... 12 McKinsey & Company.................... 13 Melinta Therapeutics ..................... 33 Mercer/Marsh .................................. 1 Morgan Stanley.............................. 41 New Jersey Health Foundation ..... 10 Novartis.......................................... 38 Pfizer .............................................. 21 Princeton University....................... 27 PTC Therapeutics........................... 19 Regional Cancer Care Associates .. 16 RSM................................................ 11 Rutgers Office for Research........... 29 Sampled ......................................... 30 Teva Pharmaceuticals ..................... 23 Thermo Fisher Scientific................... 2 USI Insurance ................................. 25 Venable........................................... 40 Viatris (Oyster Point)...................... 31 43